Speaker Testimonials

Brenda Schulman

"This meeting offers a great opportunity to learn the latest in the rapidly advancing field of targeted protein degradation"

Brenda Schulman
Director of Molecular Machines and Signaling & Acting Executive Director
Max Planck Institute of Biochemistry

Ivan Dikic
Director of Institute of Biochemistry II
Goethe University Frankfurt

Ivan Dikic

"I look forward to exchanging ideas on current progress in the area of PROTAC and AUTAC technologies"

David Rubinsztein

David Rubinsztein
Professor of Molecular Neurogenetics & UK Dementia Research Institute
University of Cambridge

"There has been increasing interest and evidence for the therapeutic potential of modulating clearance pathways,
along with exciting developments in targeting such processes. This is critical for my interest in neurodegenerative diseases and why I look forward to taking part at this meeting
"

"I hope to get insights into successful ways to develop medicines based on targeted protein degradation"

Thomas Hayhow

Thomas Hayhow
Medicinal Chemist
AstraZeneca

Terry Rabbitts

Terry Rabbitts
Professor of Molecular Immunology, The Institute of Cancer
AstraZeneca

"Developments in protein engineering coupled with delivery methods will be a major step in therapy development. This meeting will provide an important forum for discussing these issues with reference to targeted protein degradation"

Georg Winter
Principal Investigator
CeMM Research Centre for Molecular Medicine

Georg Winter cut -min

"Participation in this meeting will allow me to connect with leaders in academia and industry, exchange thoughts, explore possibilities for collaborations and to further extend the research of my academic lab to impact definitive drug development efforts"